modelIfosfamide

Diagram of Ifosfamide

Extends from Pharmacolibrary.Drugs.ATC.L.L01AA06.

Information

name:Ifosfamide
ATC code:L01AA06
route:intravenous
compartments:2
dosage:1200mg
volume of distribution:35.6L
clearance:5.2L/h
other parameters in model implementation

Ifosfamide is an alkylating agent of the oxazaphosphorine group, used primarily as a chemotherapeutic agent for the treatment of various cancers including testicular cancer, sarcomas, and lymphomas. It is an FDA-approved cytotoxic drug commonly administered in combination with other chemotherapeutics.

Pharmacokinetics

Pharmacokinetic parameters reported in adult cancer patients (various types, both sexes), administered as intravenous infusion.

References

  1. Reif, S, et al., & Jaehde, U (2002). Population pharmacokinetics of etoposide. International journal of clinical pharmacology and therapeutics 40(12) 578–579. DOI:10.5414/cpp40578 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12503821

  2. Kerbusch, T, et al., & Beijnen, JH (2001). Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. Cancer chemotherapy and pharmacology 48(1) 53–61. DOI:10.1007/s002800100277 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11488525

  3. Kerbusch, T, et al., & Beijnen, JH (2001). Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. European journal of clinical pharmacology 57(6-7) 467–477. DOI:10.1007/s002280100322 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11699611

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)